CA3143269A1 - Compositions and methods for the treatment of human immunodeficiency virus - Google Patents

Compositions and methods for the treatment of human immunodeficiency virus Download PDF

Info

Publication number
CA3143269A1
CA3143269A1 CA3143269A CA3143269A CA3143269A1 CA 3143269 A1 CA3143269 A1 CA 3143269A1 CA 3143269 A CA3143269 A CA 3143269A CA 3143269 A CA3143269 A CA 3143269A CA 3143269 A1 CA3143269 A1 CA 3143269A1
Authority
CA
Canada
Prior art keywords
conjugate
optionally substituted
pharmaceutically acceptable
formula
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3143269A
Other languages
English (en)
French (fr)
Inventor
Allen Borchardt
Thomas P. Brady
Zhi-yong CHEN
Quyen-Quyen Thuy Do
Wanlong Jiang
Leslie W. Tari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cidara Therapeutics Inc
Original Assignee
Cidara Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cidara Therapeutics Inc filed Critical Cidara Therapeutics Inc
Publication of CA3143269A1 publication Critical patent/CA3143269A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3143269A 2019-06-13 2020-06-12 Compositions and methods for the treatment of human immunodeficiency virus Pending CA3143269A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US201962861148P 2019-06-13 2019-06-13
US62/861,148 2019-06-13
US201962897952P 2019-09-09 2019-09-09
US62/897,952 2019-09-09
US201962973790P 2019-10-25 2019-10-25
US62/973,790 2019-10-25
US202062959557P 2020-01-10 2020-01-10
US62/959,557 2020-01-10
US202062970549P 2020-02-05 2020-02-05
US62/970,549 2020-02-05
US202062984557P 2020-03-03 2020-03-03
US62/984,557 2020-03-03
PCT/US2020/037601 WO2020252393A1 (en) 2019-06-13 2020-06-12 Compositions and methods for the treatment of human immunodeficiency virus

Publications (1)

Publication Number Publication Date
CA3143269A1 true CA3143269A1 (en) 2020-12-17

Family

ID=73781538

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3143269A Pending CA3143269A1 (en) 2019-06-13 2020-06-12 Compositions and methods for the treatment of human immunodeficiency virus

Country Status (7)

Country Link
US (1) US20230079107A1 (zh)
EP (1) EP3982993A1 (zh)
JP (1) JP2022536740A (zh)
CN (1) CN114401731A (zh)
AU (1) AU2020291469A1 (zh)
CA (1) CA3143269A1 (zh)
WO (1) WO2020252393A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113194983A (zh) 2018-09-06 2021-07-30 奇达拉治疗公司 用于治疗病毒感染的组合物及方法
MX2022002171A (es) * 2019-08-22 2022-05-13 Cidara Therapeutics Inc Dominios fc variantes y usos de estos.
TW202220698A (zh) 2020-08-06 2022-06-01 美商席達拉醫療有限公司 蛋白質－藥物結合物之合成方法
TW202220697A (zh) 2020-08-06 2022-06-01 美商席達拉醫療有限公司 蛋白質－藥物結合物之合成方法
WO2022133281A1 (en) 2020-12-17 2022-06-23 Cidara Therapeutics, Inc. Compositions and methods for the treatment of human immunodeficiency virus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1718667B1 (en) * 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US8008453B2 (en) * 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9834597B2 (en) * 2012-09-21 2017-12-05 The Regents Of The University Of California Modified FC polypeptides, FC conjugates, and methods of use thereof
WO2018006063A1 (en) * 2016-07-01 2018-01-04 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections
US20230190950A1 (en) * 2017-01-06 2023-06-22 Cidara Therapeutics, Inc. Compositions and methods for the treatment of bacterial infections

Also Published As

Publication number Publication date
CN114401731A (zh) 2022-04-26
EP3982993A1 (en) 2022-04-20
WO2020252393A1 (en) 2020-12-17
JP2022536740A (ja) 2022-08-18
US20230079107A1 (en) 2023-03-16
AU2020291469A1 (en) 2022-02-10
WO2020252393A8 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
CA3143269A1 (en) Compositions and methods for the treatment of human immunodeficiency virus
AU2019336230B2 (en) Compositions and methods for the treatment of viral infections
CA3143156A1 (en) Macromolecule-supported aminobenzazepine compounds
US20230082611A1 (en) Compositions and methods for the treatment of respiratory syncytial virus
CA3153359A1 (en) Compositions and methods for the treatment of viral infections
WO2018128826A1 (en) Compositions and methods for the treatment of bacterial infections
CA3153626A1 (en) Compositions and methods for the treatment of respiratory syncytial virus
WO2019126353A2 (en) Compositions and methods for the treatment of bacterial infections
WO2019126341A2 (en) Compositions and methods for the treatment of bacterial infections
CA3207893A1 (en) Immunomodulatory antibody-drug conjugates
WO2024010810A2 (en) Fc conjugates including an inhibitor of cd73 and uses thereof
WO2022133281A1 (en) Compositions and methods for the treatment of human immunodeficiency virus
US20240156975A1 (en) Compositions and methods for the treatment of viral infections
RU2816717C2 (ru) Композиции и способы для лечения вирусных инфекций
WO2021081515A2 (en) Compositions and methods for the treatment of human immunodeficiency virus
TWI840407B (zh) 用於治療病毒感染之組合物及方法